Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant
strains continue to emerge, underscoring the need for additional novel mechanism inhibitors …

Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection.
Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing …

ABSTRACT The HIV-1 capsid (CA) protein plays essential roles in both early and late stages
of virl replication and has emerged as a novel drug target. We report hybrid structure-based …

People living with HIV (PLWH) have expressed concern about the life-long burden and
stigma associated with taking pills daily and can experience medication fatigue that might …

The emergence of resistance to existing classes of antiretroviral drugs necessitates finding
new HIV-1 targets for drug discovery. The viral capsid (CA) protein represents one such …

Background: The infectious human immunodeficiency virus (HIV) particle is characterized by
a conical capsid that encloses the viral RNA genome. The capsid is essential for HIV-1 …

Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV,
and can prevent new infections via pre-exposure prophylaxis,,,–. However, some people …

Recently reported HIV-1 capsid (CA) inhibitors GS-CA1 and GS-6207 (an analog of GS-
CA1) are first-in-class compounds with long-acting potential. Reportedly, both compounds …

During the assembly stage of the human immunodeficiency virus (HIV) replication cycle,
several thousand copies of the viral Gag polyprotein associate at the cell membrane and …

Human immunodeficiency virus type 1 (HIV-1) infection is dependent on the proper
disassembly of the viral capsid, or “uncoating,” in target cells. The HIV-1 capsid consists of a …